Use of Apigenin in preparation of drugs for inhibiting liver fibroblast proliferation

A fibroblast and liver technology, applied in the field of application of Apigenin in the preparation of drugs that inhibit the proliferation of liver fibroblasts, can solve the problems of lack of clinical treatment methods

Inactive Publication Date: 2018-04-03
ZIBO DINGLI PATENT INFORMATION CONSULTING CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, some anti-hepatic fibrosis treatments have appeared successively, including chemical drugs, biological agents, traditional Chinese medicine and gene therapy, etc., but the ideal clinical treatment methods are still lacking. The main links are: reduce liver damage; inhibit the activation of stellate cells, reduce the production of extracellular matrix; regulate the disorder of cytokines, promote the apoptosis of activated hepatic stellate cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of Apigenin in preparation of drugs for inhibiting liver fibroblast proliferation
  • Use of Apigenin in preparation of drugs for inhibiting liver fibroblast proliferation
  • Use of Apigenin in preparation of drugs for inhibiting liver fibroblast proliferation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Embodiment 1: the preparation of compound Apigenin tablet involved in the present invention:

[0014] Take 5 grams of the compound Apigenin, add 195 grams of dextrin, mix well, and make 1000 tablets by conventional compression.

Embodiment 2

[0015] Embodiment 2: the preparation of compound Apigenin capsules involved in the present invention:

[0016] Take 5 grams of the compound Apigenin, add 195 grams of starch, mix well, and make 1000 capsules.

[0017] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example 1

[0018] Experimental Example 1: Using the MTT method to evaluate the inhibitory effect of the compound Apigenin on liver fibrosis

[0019] 1. Method: NIH / 3T3 cell line was purchased from the cell bank of Shanghai Institute of Cellular Sciences, Chinese Academy of Sciences, cited from ATCC (American Type Culture Collection). The subconfluent NIH / 3T3 cells in the logarithmic growth phase were digested with 0.25% trypsin, washed, centrifuged, and made into 1×10 cells with DMEM culture medium (containing 10% FCS). 4 cell / ml cell suspension, the survival rate identified by trypan blue staining is greater than 95%, add 100ul per well to a 96-well plate, and store at 37°C, 5% CO 2 After 24 hours of culture and synchronous treatment, the supernatant was discarded, 200ul of DMEM culture solution (containing 10% FCS) containing different dilutions of drugs was added, cultured for 48 hours, and MTT solution was added to each well for incubation for 4 hours. Discard the culture medium, ad...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses the use of Apigenin in the preparation of medicines for treating liver fibrosis. Pharmacological tests have proved that Apigenin can significantly inhibit the occurrence and development of liver fibrosis, and can be used to prepare drugs against liver fibrosis and liver cirrhosis. Apigenin belongs to a new skeleton type, and it has strong inhibitory activity on liver fibroblast proliferation Prominent substantive features, while being used against proliferation of hepatic fibroblasts clearly represent a significant advance.

Description

technical field [0001] The present invention relates to a new application of the compound Apigenin, in particular to the application of Apigenin in the preparation of drugs for inhibiting liver fibroblast proliferation. Background technique [0002] Liver fibrosis is a dynamic process from chronic liver injury to liver cirrhosis. In the past 20 years, the research on liver fibrosis has made great progress, and it has been confirmed that liver fibrosis and liver cirrhosis are reversible to a certain extent. In recent years, some anti-hepatic fibrosis treatments have appeared successively, including chemical drugs, biological agents, traditional Chinese medicine and gene therapy, etc., but the ideal clinical treatment methods are still lacking. The main steps are: reduce liver damage; inhibit the activation of stellate cells, reduce the production of extracellular matrix; regulate the disorder of cytokines, and promote the apoptosis of activated hepatic stellate cells. [000...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K9/48A61K9/20A61P1/16
CPCA61K31/352A61K9/2059A61K9/4866
Inventor 田丽华
Owner ZIBO DINGLI PATENT INFORMATION CONSULTING CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap